Market Intelligence, Clinical Progress, and High-Purity Reagents for SMARD1 and Oncology Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IGHMBP2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length) | IGHMBP2 Recombinant Protein (1-993 aa) HEK293 Expressed, Native Glycosylation, Endotoxin <1 EU/µg, Sequence Verified |
View IGHMBP2 Products |
| Antigen (Helicase Domain) | IGHMBP2 DExD/H-box Domain (142-626 aa) ATP-binding Site Preserved, Theoretical MW 55 kDa, High Purity (>95%) |
View IGHMBP2 Products |
| Mutant Panel | IGHMBP2 Helicase-dead Mutants (K237A, R261A) For dominant negative mechanism studies, Sequence Verified |
View IGHMBP2 Products |
| Gene Delivery | IGHMBP2 Lentivirus Particles (CMV promoter) High Titer (>10^8 TU/mL), Puromycin Selection, Full ORF |
View IGHMBP2 Products |
| Validator | IGHMBP2 siRNA Set (3 unique sequences) For knockdown specificity verification, HPLC-purified |
View IGHMBP2 Products |
| Benchmark Ab | Anti-IGHMBP2 Rabbit mAb (Clone C-term) Recombinant, Validated for WB/IP, Endotoxin Controlled |
View IGHMBP2 Products |
| Related Target: SMN1 | SMN1 Primary therapeutic target for classic SMA comparison |
View SMN1 Products |
| Related Target: SETX | Senataxin, a related DNA/RNA helicase involved in motor neuron diseases | View SETX Products |
| Related Target: SBDS | SBDS (Shwachman-Bodian-Diamond Syndrome) Ribosome biogenesis partner, synergistic pathway |
View SBDS Products |
| Related Target: DDX21 | DDX21 (RNA Helicase) Parallel rRNA processing pathway, off-target screening reference |
View DDX21 Products |
| Related Target: MYC | MYC (Transcription Factor) Downstream effector in IGHMBP2-mediated proliferation |
View MYC Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Helicase Activity Quantification (ATPase/GTPase) | Full-length & Domain-specific proteins with preserved Walker A/B motifs; >95% purity essential for kinetic assays |
| Dominant Negative Mechanism Validation (SMARD1 research) | Pre-made Helicase-dead Mutants (K237A, R261A); Sequence Verified; Theoretical MW matched for SPR/BLI |
| Cross-species Gene Therapy Evaluation (Human/Mouse/Cyno) | Ortholog Protein Panel available with >98% sequence homology; Endotoxin <0.1 EU/µg for neuronal cell assays |
| RNA-binding Specificity (Off-target helicase screening) | Homolog Panel (DDX21, DDX5, DHX9) for selectivity assays; High-purity substrates for EMSA/FP |
| Compound Permeability (Intracellular target) | Cell-penetration validation using Lentivirus-stable cell lines with IGHMBP2-OE/KD controls |
Live IGHMBP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Gene Therapy Research
- ➤ Recent Patent Filings
- ➤ Resistance & Inhibitor Mechanisms
Global Clinical Landscape & Future Outlook
The therapeutic landscape for IGHMBP2 is bifurcated between rare disease monotherapy and oncology targeting. In the rare disease space (Spinal Muscular Atrophy with Respiratory Distress type 1, SMARD1), the field is transitioning from supportive care to genetic modulation, with AAV-mediated gene therapy and antisense oligonucleotides (ASOs) entering preclinical optimization. Concurrently, oncological research recognizes IGHMBP2 as a ribosome biogenesis regulator downstream of MYC, positioning it as a synthetic lethality target in hyperproliferative cancers.
"The convergence of SMARD1 gene therapy development and oncology helicase inhibitor programs is creating unprecedented demand for high-fidelity IGHMBP2 proteins—particularly dominant-negative mutants for mechanism validation and ortholog panels for cross-species immunogenicity assessment."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| AAV Gene Therapy | Novartis, Roche, Academic Consortia | SMARD1 (Spinal Muscular Atrophy) | Cross-reactivity ELISAs (Human vs Cyno vs Mouse IGHMBP2); Lentivirus for stable cell line construction prior to AAV validation |
| ASO (Antisense Oligonucleotide) | Ionis Pharmaceuticals, Biogen | SMARD1 (Splicing correction) | Knockdown Validation (IGHMBP2 siRNA Set as positive control); Specificity assays vs DDX21 |
| Small Molecule Inhibitors | Emerging Biotech, Structural Genomics Consortium | Solid Tumors (MYC-driven) | ATPase Activity Assay (Need Walker motif intact proteins); Dominant negative mutant controls (K237A) |
| Protein Replacement | Preclinical Academic Groups | SMARD1 | Endotoxin-controlled (<0.1 EU/µg) full-length protein; Stability at physiological pH |
Molecular Differentiation Requirements
For SMARD1 therapeutics, efficacy depends on restoring helicase activity without dominant-negative interference, necessitating wild-type protein with validated ATP-binding capacity. For oncology inhibitors, specificity against the DExD/H-box helicase family (DDX21, DDX5) is the primary differentiator, requiring rigorous off-target screening panels.
IGHMBP2 contains an UPF1-type SF1B helicase ATP-binding domain, a C-terminal domain, and an R3H domain, which are critical for its helicase activity. Key mutations associated with HMNR1 include dbSNP:rs1594412120 and dbSNP:rs879253996; a common polymorphism rs2228206 is also documented.
Key technical specifications for IGHMBP2 assays:
- ATP-binding Site Integrity: Walker A (P-loop) and Walker B motifs must be conformationally accessible for helicase activity assays
- Dominant Negative Controls: K237A (ATP-binding defective) and R261A (RNA-binding defective) mutants essential for mechanism-of-action studies
- Endotoxin Sensitivity: Neuronal and muscle cell assays require <0.1 EU/µg to prevent false cytotoxicity signals
- Cross-species Epitopes: Gene therapy immunogenicity studies require 1:1 ortholog protein pairs (Human/Mouse/Cyno)